Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Yimitasvir - HEC Pharm

Next Previous
Search
Drug Profile

Yimitasvir - HEC Pharm

Alternative Names: DAG 181; Yimitasvir phosphate

Latest Information Update: 07 Sep 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator HEC Pharm
  • Developer Dongguan HEC TaiGen Biopharmaceuticals; HEC Pharm
  • Class Amines; Antivirals; Benzimidazoles; Carbamates; Imidazoles; Pyrrolidines; Small molecules
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hepatitis C

Most Recent Events

  • 07 Sep 2022 Yimitasvir is still in phase III trials for Hepatitis C (Combination therapy, Treatment-naïve, Treatment-experienced) in China (HEC Pharm pipeline, September 2022)
  • 09 Jun 2022 Sunshine Lake Pharma completes a phase I trial for Hepatitis C (In volunteers) in China (NCT04552808)
  • 07 May 2022 Sunshine Lake Pharma completes a phase I pharmacokinetic trial in Healthy volunteers in China (PO, Capsule) (NCT04565171)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top